Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2012 Jul;56(7):4005–4008. doi: 10.1128/AAC.00598-12

Substrate Spectrum Extension of PenA in Burkholderia thailandensis with a Single Amino Acid Deletion, Glu168del

Hyojeong Yi a, Karan Kim a, Kwang-Hwi Cho b, Oksung Jung b, Heenam Stanley Kim a,
PMCID: PMC3393396  PMID: 22564834

Abstract

We describe a deletion mutation in a class A β-lactamase, PenA, of Burkholderia thailandensis that extended the substrate spectrum of the enzyme to include ceftazidime. Glu168del was located in a functional domain called the omega loop causing expansion of the space in the loop, which in turn increased flexibility at the active site. This deletion mutation represents a rare but significant alternative mechanical path to substrate spectrum extension in PenA besides more common substitution mutations.

TEXT

Burkholderia pseudomallei is the etiological agent of septicemic melioidosis, which is endemic in Southeast Asia and northeastern Australia (4). Burkholderia mallei, the cause of glanders, is a species derived from a clone of B. pseudomallei (20). Bcc, which is a complex composed of more than 10 Burkholderia species, including Burkholderia cepacia, Burkholderia cenocepacia, and Burkholderia multivorans, is a group of nosocomial pathogens that cause respiratory and systemic infections in patients with cystic fibrosis or chronic granulomatous disease and in other immunocompromised patients (10). The antibiotic regimen used to treat infections with these bacteria generally includes ceftazidime (10, 26). To date, only a few cases of ceftazidime resistance in Burkholderia spp. have been reported and resistance has pointed mostly to a single gene, penA. Two single amino acid substitutions, Pro167Ser and Cys69Tyr (amino acid residue numbering according to Ambler et al. [1]), have been described in PenA of ceftazidime-resistant B. pseudomallei isolates (15, 17, 18, 22). Similarly, two orthologs of PenA, PenB2 and PenB3, with seven and two amino acid alterations, respectively, were shown to be associated with ceftazidime resistance in clinical isolates of B. cenocepacia (13).

Here we report a new mutation that extends to ceftazidime the substrate spectrum of PenA of B. thailandensis (3) (BTH_II1450 of B. thailandensis strain E264), which is closely related to PenA enzymes of the pathogenic species B. pseudomallei, B. mallei, and Bcc (13, 17, 22). The resistant isolate arose against a high level of ceftazidime (5 μg/ml) in LB medium. The MIC of ceftazidime for this isolate was 48 μg/ml, which was significantly higher than the 1.75 μg/ml of the wild type (Fig. 1). By PCR amplifying penA from its genomic DNA using primers penA-F (5′-CGTCAATCCGATGCAGTACC-3′) and penA-R (5′-GCCGTTATCGCACCTTTATC-3′) and sequencing the amplicon in both directions using a 3730XL DNA analyzer (Applied Biosystems, Foster City, CA), we found a three-base deletion mutation in the coding region of penA (Fig. 1). To confirm that this penA gene with the mutation was responsible for the ceftazidime resistance that developed in the mutants, we inactivated the penA gene by replacing a region spanning 196 bp in the middle of the coding region with a Tetr cassette, which was obtained from broad-host-range vector pRK415K (9). The penA-null mutant was verified by PCR using primers penA_LF (5′-AACAGATCGCCGAGATGG-3′) and penA_LR (5′-GCGAACGTTGCCCGATAC-3′), which hybridize to the genomic regions outside penA. The mutant strain with inactivated penA-Glu168del (that is, with ΔpenA-Glu168del) lost resistance to ceftazidime, whose MIC was comparable to that for the wild-type strain with ΔpenA-WT (Fig. 1). The MICs were measured by the Etest (8) in accordance with the manufacturer's instructions (AB Biodisk, Solna, Sweden). When a mutant strain with ΔpenA-Glu168del was provided with an intact copy of penA-Glu168del in trans, carried by pRK415K, ceftazidime resistance was restored (Fig. 1), indicating that penA was the factor responsible for ceftazidime resistance.

Fig 1.

Fig 1

A single amino acid deletion mutation in PenA. The PenA protein is represented by an arrow in which four conserved domains of sequences and the omega loop common to class A β-lactamases (11) are indicated. The positions are numbered according to Ambler et al. (1). B. thailandensis strain E264 with the intact penA allele (penA-WT) and others with various penA alleles are listed, and the MICs of ceftazidime (CAZ) are shown in the bar graph. Complemented strains contain the penA alleles, corresponding to the disrupted genes, carried by plasmid pRK415K.

The mutation resulted in the deletion of an amino acid residue located in the omega loop, a structural domain constituting part of the active-site pocket (7, 16). Specifically, this deleted residue Glu168, which is the first of the three residues constituting the helical structure in the middle of the loop and is also located in a conserved domain in class A β-lactamases 166EXXLN170 (numbering according to Ambler et al. [1]) (11) (Fig. 1). Glu168del artificially constructed in TEM-1 resulted in ceftazidime resistance in Escherichia coli (19). However, this deletion mutation has never been found in natural variants of class A β-lactamases, including TEM and SHV enzymes (TEM and SHV tables summarizing variants in each group can be found at http://www.lahey.org/Studies/).

To investigate the structural change in PenA that correlates with the substrate spectrum extension to ceftazidime, we conducted modeling analyses using SED-1 (Protein Data Bank identification code 3BFE; 54% amino acid sequence identity to PenA) (12) as a template with SYBYL-X (Tripos Inc., St. Louis, MO). With the predicted structures, molecular dynamic simulations were conducted using OpenMM Zephyr 2.0.3 (6) for 500 ps (0.002 ps/step) at 303.15 K with the Amber03 force field to release any structural constraints originating from the template. Energy minimization was then performed using SYBYL-X (Tripos Inc., St. Louis, MO) with a Tripos force field until the energy gradient reached 0.001 kcal/(mol · Å). We chose SED-1 for the simulation because, similar to wild-type PenA, it does not hydrolyze ceftazidime and also has high homology to PenA. In our simulation, the size and shape of the binding pocket did not show significant changes resulting from the amino acid deletion. Instead, we observed that Glu168del resulted in disruption of the α-helix structure in the omega loop and increased distance between positions 164 and 179, possibly affecting the stabilizing salt bridge between the two residues that clamp the omega loop structure at both ends (7) (Fig. 2). This, in turn, suggests that the possible disruption of the ionic bond between residues 164 and 179 may destabilize the omega loop (11, 14, 23). In addition, we noted that the space in the omega loop (calculated as the distances between amino acid residues 163 and 174 and between 164 and 173) increased in the mutated PenA sequence compared to that in the wild-type PenA sequence, notably between 164 and 173 (Fig. 2). We postulate that the removal of the α-helix structure and increased space in the omega loop may accompany increased flexibility of the loop in the mutant enzymes. This flexibility would then, in turn, relieve steric hindrance between the omega loop and the bulky 7β side chain of ceftazidime, thereby increasing the accessibility of ceftazidime to the binding pocket (25).

Fig 2.

Fig 2

Altered α-helix structure and the internal space in the omega loop of PenA. Glu168del resulted in disruption of the α-helix structure and expansion of the internal space in the omega loop. The measured distances are designated A, B, and C in the simulated three-dimensional omega loop structure. The distance between positions 164 and 179, where the ionic bond is present (at least in the wild type), in PenA-Glu168del is compared to that in the wild type in the bar graph. The distances between positions 164 and 173 and positions 163 and 174 in the omega loop, representing the internal space of the omega loop, are also compared to those in the wild type in the bar graph.

To investigate the extent to which the structural changes in PenA that were adjusted to ceftazidime affect the enzyme's activity toward other β-lactam antibiotics, we measured the MICs of selected β-lactam antibiotics. These antibiotics included the four that the wild-type enzyme was able to hydrolyze, a carbapenem antibiotic (meropenem), and a β-lactamase inhibitor (clavulanic acid with amoxicillin). Mutated PenA exhibited decreased levels of resistance to the original substrates, as observed in many mutant forms of the class A β-lactamase that acquired activity against broad-spectrum cephalosporins (24) (Table 1). The hydrolytic activity of the mutated PenA enzyme against amoxicillin was effectively inhibited by clavulanic acid. In addition, resistance to meropenem was not observed in the wild type or the mutant (Table 1).

Table 1.

MICs of various β-lactams for B. thailandensis strains

Strain MIC (μg/ml)a
AMX AMX-CLA CTXM CRX CEF MER
Wild-type E264 (penA-WT) 36 6 6 16 18 0.75
Mutant E264 (penA-Glu168del) 4 2.25 4.5 2.5 9 0.63
penA-null mutants
    E264 (ΔpenA-WT) 4 1.5 1 0.5 3 0.75
    E264 (ΔpenA-Glu168del) 3 2.25 0.75 0.22 3 0.38
Complemented penA-null mutantsb
    E264 (ΔpenA-WT, complemented) >256 48 >32 >32 64 0.75
    E264 (ΔpenA-Glu168del, complemented) 10 2.25 12 12 48 1.13
a

MICs were measured by the Etest. Abbreviations: AMX, amoxicillin; AMX-CLA, amoxicillin-clavulanic acid; CTXM, cefotaxime; CRX, ceftriaxone; CEF, cefepime; MER, meropenem.

b

Complemented with penA alleles carried by pRK415K.

The levels of ceftazidime resistance in clinical B. pseudomallei isolates (5, 21) and in Bcc (2, 16) have been determined to be low. However, the continued use of ceftazidime in clinical settings suggests a high potential for the increased emergence of ceftazidime resistance in these bacterial groups. In this regard, predetermination of possible mutations in PenA capable of altering the substrate spectrum of the enzyme is significant. Furthermore, these data have substantial value, as they suggest that Glu168del, which was characterized only in an artificially constructed TEM-1 derivative (19), indeed is highly likely to occur in natural settings in PenA.

ACKNOWLEDGMENTS

This work was supported by grants 20090088364 from the Basic Research Program and 20110016847 from the Core Research Program, both of which are from the Ministry of Education, Science & Technology of the Republic of Korea. Additional support was provided by the Korea Foundation for International Cooperation of Science & Technology (KICOS) through a grant provided by the Korean Ministry of Science & Technology (MOST) in K20903001812-11E0100-01700 to H.S.K.

Footnotes

Published ahead of print 7 May 2012

REFERENCES

  • 1. Ambler RP, et al. 1991. A standard numbering scheme for the class A beta-lactamases. Biochem. J. 276(Pt 1):269–270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Bonacorsi S, Fitoussi F, Lhopital S, Bingen E. 1999. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 43:213–217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Brett PJ, DeShazer D, Woods DE. 1998. Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int. J. Syst. Bacteriol. 48(Pt 1):317–320 [DOI] [PubMed] [Google Scholar]
  • 4. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev. 18:383–416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Dance DAB, Wuthiekanun V, Chaowagul W, White NJ. 1989. The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J. Antimicrob. Chemother. 24:295–309 [DOI] [PubMed] [Google Scholar]
  • 6. Friedrichs MS, et al. 2009. Accelerating molecular dynamic simulation on graphics processing units. J. Comput. Chem. 30:864–872 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Jelsch C, Mourey L, Masson JM, Samama JP. 1993. Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution. Proteins 16:364–383 [DOI] [PubMed] [Google Scholar]
  • 8. Joyce LF, Downes J, Stockman K, Andrew JH. 1992. Comparison of five methods, including the PDM Epsilometer test (E test), for antimicrobial susceptibility testing of Pseudomonas aeruginosa. J. Clin. Microbiol. 30:2709–2713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Keen NT, Tamaki S, Kobayashi D, Trollinger D. 1988. Improved broad-host-range plasmids for DNA cloning in Gram-negative bacteria. Gene 70:191–197 [DOI] [PubMed] [Google Scholar]
  • 10. Leitão JH, et al. 2010. Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species. Appl. Microbiol. Biotechnol. 87:31–40 [DOI] [PubMed] [Google Scholar]
  • 11. Matagne A, Lamotte-Brasseur J, Frere JM. 1998. Catalytic properties of class A beta-lactamases: efficiency and diversity. Biochem. J. 330:581–598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Petrella S, Clermont D, Casin I, Jarlier V, Sougakoff W. 2001. Novel class A β-lactamase Sed-1 from Citrobacter sedlakii: genetic diversity of β-lactamases within the Citrobacter genus. Antimicrob. Agents Chemother. 45:2287–2298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Poirel L, Rodriguez-Martinez J-M, Plesiat P, Nordmann P. 2009. Naturally occurring class A beta-lactamases from the Burkholderia cepacia complex. Antimicrob. Agents Chemother. 53:876–882 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Raquet X, et al. 1994. TEM beta-lactamase mutants hydrolysing third-generation cephalosporins: a kinetic and molecular modelling analysis. J. Mol. Biol. 244:625–639 [DOI] [PubMed] [Google Scholar]
  • 15. Rholl DA, et al. 2011. Molecular investigations of PenA-mediated β-lactam resistance in Burkholderia pseudomallei. Front. Microbiol. 2:139 doi:10.3389/fmicb.2011.00139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Saika T, Kobayashi I, Hasegawa M, Nishida M. 2002. Antimicrobial resistance and DNA-fingerprinting pattern of Burkholderia cepacia blood isolates. J. Infect. Chemother. 8:341–344 [DOI] [PubMed] [Google Scholar]
  • 17. Sam IC, See KH, Puthucheary SD. 2009. Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei. J. Clin. Microbiol. 47:1556–1558 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Sarovich DS, et al. 2012. Characterization of ceftazidime resistance mechanisms in clinical isolates of Burkholderia pseudomallei from Australia. PLoS One 7:e30789 doi:10.1371/journal.pone.0030789 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Simm AM, Baldwin AJ, Busse K, Jones DD. 2007. Investigating protein structural plasticity by surveying the consequence of an amino acid deletion from TEM-1 β-lactamase. FEBS Lett. 581:3904–3908 [DOI] [PubMed] [Google Scholar]
  • 20. Song H, et al. 2010. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 6:e1000922 doi:10.1371/journal.ppat.1000922 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. 2004. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother. 54:1134–1138 [DOI] [PubMed] [Google Scholar]
  • 22. Tribuddharat C, Moore RA, Baker P, Woods DE. 2003. Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition. Antimicrob. Agents Chemother. 47:2082–2087 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Vakulenko SB, Toth M, Taibi P, Mobashery S, Lerner SA. 1995. Effects of Asp-179 mutations in TEMpUC19 beta-lactamase on susceptibility to beta-lactams. Antimicrob. Agents Chemother. 39:1878–1880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Wang X, Minasov G, Shoichet BK. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320:85–95 [DOI] [PubMed] [Google Scholar]
  • 25. Wong W-T, et al. 2011. Increased structural flexibility at the active site of a fluorophore-conjugated β-lactamase distinctively impacts its binding toward diverse cephalosporin antibiotics. J. Biol. Chem. 286:31771–31780 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Wuthiekanun V, Peacock SJ. 2006. Management of melioidosis. Expert Rev. Anti Infect. Ther. 4:445–455 [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES